NKGen Biotech secures stockholder approval for stock issuance By Investing.com

In a decisive move, shareholders of NKGen Biotech, Inc. (Nasdaq: NKGN), a Delaware-based company specializing in biological products, have given the green light to a proposal that could significantly affect the company’s capital structure.

During the annual meeting held on Wednesday, stockholders approved the potential issuance of shares amounting to more than 19.99% of the company’s current outstanding common stock, in accordance with Nasdaq listing rules.

The approval was part of the annual stockholders’ meeting agenda, where voting also took place for the election of a Class I director.

Marco Gottardis, the nominee for the position, was elected with an overwhelming majority to serve a three-year term or until his successor is elected and qualified, or until his earlier resignation or removal.

The specific voting results for the director election showed 15,726,874 votes in favor, 15,351 against, and 3,246 abstentions. The proposal regarding the issuance of additional shares passed with 15,677,501 votes for, 64,640 against, and 3,330 abstentions.

InvestingPro Insights

As NKGen Biotech, Inc. navigates the competitive biotech landscape, recent market data from InvestingPro provides a snapshot of the company’s financial position. With a market capitalization of $19.67 million, NKGen Biotech’s stock has faced significant challenges, evidenced by a price that is currently hovering near its 52-week low and a steep year-to-date price total return of -72.24%. The company’s operational performance over the last twelve months, as of Q1 2024, reveals substantial losses, with an operating income of -$30.57 million and an EBITDA of -$29.38 million.

InvestingPro Tips indicate that NKGen Biotech has struggled with weak gross profit margins and liquidity concerns, as short-term obligations exceed its liquid assets. Additionally, the company has not been profitable over the last twelve months and does not pay a dividend to shareholders. These factors, combined with a stock price that has fallen significantly over the past year (-92.62%), could be of interest to investors considering the company’s decision to potentially issue additional shares.

For investors seeking a more comprehensive understanding of NKGen Biotech’s financial health and future prospects, InvestingPro offers additional tips. Visit https://www.investing.com/pro/NKGN to explore the full range of insights and analytics available.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.